The effect of istradefylline for Parkinson’s disease: A meta-analysis
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The effect of istradefylline for Parkinson’s disease: A meta-analysis
Authors
Keywords
-
Journal
Scientific Reports
Volume 7, Issue 1, Pages -
Publisher
Springer Nature
Online
2017-12-15
DOI
10.1038/s41598-017-18339-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Istradefylline improves daytime sleepiness in patients with Parkinson's disease: An open-label, 3-month study
- (2017) Keisuke Suzuki et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Parkinson's disease-related network topographies characterized with resting state functional MRI
- (2016) An Vo et al. HUMAN BRAIN MAPPING
- Clinical efficacy of istradefylline on lower urinary tract symptoms in Parkinson's disease
- (2016) Takeya Kitta et al. INTERNATIONAL JOURNAL OF UROLOGY
- The difference of apparent diffusion coefficient in the middle cerebellar peduncle among parkinsonian syndromes: Evidence from a meta-analysis
- (2016) Wataru Sako et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Distinct brain networks underlie cognitive dysfunction in Parkinson and Alzheimer diseases
- (2016) Paul J. Mattis et al. NEUROLOGY
- A Long-Term Study of Istradefylline Safety and Efficacy in Patients With Parkinson Disease
- (2015) Tomoyoshi Kondo et al. CLINICAL NEUROPHARMACOLOGY
- Efficacy of Adenosine A2A Receptor Antagonist Istradefylline as Augmentation for Parkinson’s Disease: A Meta-analysis of Randomized Controlled Trials
- (2014) Yingqun Tao et al. CELL BIOCHEMISTRY AND BIOPHYSICS
- Which target is best for patients with Parkinson's disease? A meta-analysis of pallidal and subthalamic stimulation
- (2014) W. Sako et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Reduced alpha-synuclein in cerebrospinal fluid in synucleinopathies: Evidence from a meta-analysis
- (2014) Wataru Sako et al. MOVEMENT DISORDERS
- Reports of Pathological Gambling, Hypersexuality, and Compulsive Shopping Associated With Dopamine Receptor Agonist Drugs
- (2014) Thomas J. Moore et al. JAMA Internal Medicine
- Dopamine agonist monotherapy in Parkinson's disease and potential risk factors for dyskinesia: a meta-analysis of levodopa-controlled trials
- (2013) M. Chondrogiorgi et al. EUROPEAN JOURNAL OF NEUROLOGY
- Adenosine A2Areceptor antagonist istradefylline reduces daily OFF time in Parkinson's disease
- (2013) Yoshikuni Mizuno et al. MOVEMENT DISORDERS
- Caffeine consumption and risk of dyskinesia in CALM-PD
- (2013) Anne-Marie A. Wills et al. MOVEMENT DISORDERS
- Istradefylline, an adenosine A2A receptor antagonist, for patients with Parkinson's Disease: A meta-analysis
- (2012) Wanqiang Chen et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Adenosine A2A receptor gene disruption protects in an α-synuclein model of Parkinson's disease
- (2011) Anil Kachroo et al. ANNALS OF NEUROLOGY
- Modulation of Striatal Projection Systems by Dopamine
- (2011) Charles R. Gerfen et al. Annual Review of Neuroscience
- Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease
- (2011) A. F. Ramlackhansingh et al. NEUROLOGY
- Istradefylline for Parkinson's disease patients experiencing motor fluctuations: Results of the KW-6002-US-018 study
- (2011) Emmanuelle Pourcher et al. PARKINSONISM & RELATED DISORDERS
- Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: The STRIDE-PD study
- (2010) Fabrizio Stocchi et al. ANNALS OF NEUROLOGY
- Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: A randomized, controlled study
- (2010) Yoshikuni Mizuno et al. MOVEMENT DISORDERS
- Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry
- (2010) Alexxai V. Kravitz et al. NATURE
- Long-term Effect of Initiating Pramipexole vs Levodopa in Early Parkinson Disease
- (2009) ARCHIVES OF NEUROLOGY
- Istradefylline as monotherapy for Parkinson disease: Results of the 6002-US-051 trial
- (2009) H.H. Fernandez et al. PARKINSONISM & RELATED DISORDERS
- Adenosine A2Areceptor antagonist istradefylline (KW-6002) reduces “off” time in Parkinson's disease: A double-blind, randomized, multicenter clinical trial (6002-US-005)
- (2008) Peter A. LeWitt et al. ANNALS OF NEUROLOGY
- Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations
- (2008) Robert A. Hauser et al. MOVEMENT DISORDERS
- A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease
- (2008) M. Stacy et al. NEUROLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More